Literature DB >> 697345

Pharmacokinetics of cefaclor and cephalexin: dosage nomograms for impaired renal function.

D A Spyker, B L Thomas, M A Sande, W K Bolton.   

Abstract

The pharmacokinetics of cefaclor and cephalexin were characterized in patients with creatinine clearances ranging from 0 to 147 ml/min. Each of 24 fasted subjects received a single 500-mg oral dose of cefaclor, and 13 of these subjects later received 500 mg of cephalexin. Serum and urine levels of the antibiotics were measured by bioassay. The serum half-lives were highly correlated with corrected creatinine clearance (cefaclor r = 0.92, cephalexin r = 0.94). Linear regression estimates of the half-life of cefaclor were 2.3 h in the anephric patient and 40 min in the patient with a corrected creatinine clearance of 100 ml/min. For cephalexin, corresponding half-lives were 15.4 h and 58 min. We present a dosage nomogram for calculating the appropriate adjustments to the loading dose based on patient weight and maintenence dose based on corrected creatinine clearance.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 697345      PMCID: PMC352429          DOI: 10.1128/AAC.14.2.172

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  10 in total

Review 1.  Pharmacokinetics and clinical use of cephalosporin antibiotics.

Authors:  C H Nightingale; D S Greene; R Quintiliani
Journal:  J Pharm Sci       Date:  1975-12       Impact factor: 3.534

2.  Pharmacokinetics of cephalexin: an evaluation of one- and two-compartment model pharmacokinetics.

Authors:  D S Greene; D R Flanagan; R Quintiliani; C H Nightingale
Journal:  J Clin Pharmacol       Date:  1976 May-Jun       Impact factor: 3.126

3.  Metabolism of (14C) cefaclor, a cephalosporin antibiotic, in three species of laboratory animals.

Authors:  H R Sullivan; S L Due; D L Kau; J F Quay; W Miller
Journal:  Antimicrob Agents Chemother       Date:  1976-10       Impact factor: 5.191

4.  Pharmacokinetics of cefaclor in normal subjects and patients with chronic renal failure.

Authors:  R Bloch; J J Szwed; R S Sloan; F C Luft
Journal:  Antimicrob Agents Chemother       Date:  1977-12       Impact factor: 5.191

5.  Comparative pharmacology of cefaclor and cephalexin.

Authors:  O M Korzeniowski; W M Scheld; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

6.  In vitro susceptibility studies with cefaclor and cephalexin.

Authors:  W M Scheld; O M Korzeniowski; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1977-08       Impact factor: 5.191

7.  Gentamicin serum concentrations: pharmacokinetic predictions.

Authors:  J H Hull; F A Sarubbi
Journal:  Ann Intern Med       Date:  1976-08       Impact factor: 25.391

8.  Gentamicin dosage.

Authors: 
Journal:  Ann Intern Med       Date:  1977-03       Impact factor: 25.391

9.  Pharmacokinetics of amoxicillin: dose dependence after intravenous, oral, and intramuscular administration.

Authors:  D A Spyker; R J Rugloski; R L Vann; W M O'Brien
Journal:  Antimicrob Agents Chemother       Date:  1977-01       Impact factor: 5.191

10.  Determination of cefalexin pharmacokinetics and dosage adjustments in relation to renal function.

Authors:  J M Brogard; M Pinget; M Dorner; J Lavillaureix
Journal:  J Clin Pharmacol       Date:  1975-10       Impact factor: 3.126

  10 in total
  8 in total

1.  Cefaclor: summary of clinical experience.

Authors:  R B Kammer; L J Short
Journal:  Infection       Date:  1979       Impact factor: 3.553

2.  Comparative pharmacokinetics of cephalexin, cefaclor, cefadroxil, and CGP 9000.

Authors:  H Lode; R Stahlmann; P Koeppe
Journal:  Antimicrob Agents Chemother       Date:  1979-07       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of antibiotics in patients with impaired renal function.

Authors:  W L St Peter; K A Redic-Kill; C E Halstenson
Journal:  Clin Pharmacokinet       Date:  1992-03       Impact factor: 6.447

4.  Interethnic differences of PEPT2 (SLC15A2) polymorphism distribution and associations with cephalexin pharmacokinetics in healthy Asian subjects.

Authors:  Rui Liu; Audrey May Yi Tang; Yen Ling Tan; Lie Michael George Limenta; Edmund Jon Deoon Lee
Journal:  Eur J Clin Pharmacol       Date:  2008-09-03       Impact factor: 2.953

5.  Mass balance approaches for estimating the intestinal absorption and metabolism of peptides and analogues: theoretical development and applications.

Authors:  P J Sinko; G D Leesman; G L Amidon
Journal:  Pharm Res       Date:  1993-02       Impact factor: 4.200

6.  Pharmacokinetics of cefaclor in renal failure: effects of multiple doses and hemodialysis.

Authors:  D A Spyker; L L Gober; W M Scheld; M A Sande; W K Bolton
Journal:  Antimicrob Agents Chemother       Date:  1982-02       Impact factor: 5.191

7.  Pharmacokinetics of moxalactam in subjects with various degrees of renal dysfunction.

Authors:  W K Bolton; W M Scheld; D A Spyker; T L Overby; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1980-12       Impact factor: 5.191

8.  Population Pharmacokinetic Analysis of Cefaclor in Healthy Korean Subjects.

Authors:  Seung-Hyun Jeong; Ji-Hun Jang; Hea-Young Cho; Yong-Bok Lee
Journal:  Pharmaceutics       Date:  2021-05-19       Impact factor: 6.321

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.